Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions

Tohoku Journal of Experimental Medicine

Volumn 205, Issue 1, 2005, Pages 11-18

  Kemer, Türker ^a   Ormen, Murat ^a   Kuralay, Filiz ^a   Pehlivan, Mustafa ^b   Unsal, Belkis ^c   Tankurt, Ethem ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Ataturk State Hospital   (Turkey)

Author keywords

Cancer; Carbohydrate antigen 125(CA 125); Cirrhosis; Peritoneal effusion; Spontaneous bacterial peritonitis

Indexed keywords

BIOCHEMICAL MARKER; CA 125 ANTIGEN; TUMOR MARKER;

ABDOMINAL CANCER; ADULT; ALCOHOL LIVER CIRRHOSIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; BUDD CHIARI SYNDROME; CANCER DIAGNOSIS; CANCER PATIENT; CHEMOLUMINESCENCE; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PERITONEAL FLUID; PERITONEUM EXUDATE; PRIMARY BILIARY CIRRHOSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STOMACH CANCER;

ASCITIC FLUID; CA-125 ANTIGEN; FIBROSIS; HUMANS; NEOPLASMS; PERITONITIS; ROC CURVE;

EID: 13844321908     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.205.11     Document Type: Article

References (35)

1. Bergmann, J.F., Bidart, J.M., George M., Beaugrand, M., Levy, V.G. & Bohuon, C. (1987) Elevation of CA- 125 in patients with benign and malignant ascites. Cancer, 59, 213-217.
2. Chi, C.H., Shiesh, S.C., Chen, K.W., Wu, M.H. & Lin, X.Z. (1996) C-reactive protein for the evaluation of acute abdominal pain. Am. J. Emerg. Med., 14, 254-256.
3. Collazas, J., Genolla, J. & Ruibal, A. (1992) CA-125 levels patients with non-neoplastic liver diseases. A clinical and laboratory study. Scand. J. Clin. Lab. Invest., 52, 201-206.
4. Devarbhavi, H., Kaese, D., Williams, A.W., Rakela, J., Klee, G.G. & Kamath, P. (2002) Cancer Antigen 125 in patients with chronic liver disease. Mayo Clin. Proc., 77, 538-541.
5. Epiney, M., Bertossa, C., Weil, A., Campana, A. & Bischof, P. (2000) CA-125 production by peritoneum: in-vitro and in-vivo studies. Hum. Reprod., 15, 1261-1265.
6. Fujimura, T., Kinami, S., Ninomiya, I., Kitagawa, H., Fushida, S., Nishimura, G., Kayahara, M., Shimizu, K., Ohta, T. & Miwa, K. (2002) Diagnostic laparoscopy, serum CA125 and peritoneal metastasis in gastric cancer. Endoscopy, 34, 569-574.
7. Haglund, C., Kuusela, P., Roberts, P. & Jalanko, H. (1991) Tumor marker CA-125 in patients with digestive tract malignancies. Scand. J. Clin. Lab. Invest., 51, 265-270.
8. Haglund, C. & Kuusela, P. (1999) Tumor marker CA-125 in patients with digestive tract malignancies. Scand. J. Clin. Invest. 51, 265-270.
9. Halila, H., Stenman, U.H. & Seppala, M. (1986) Ovarian cancer antigen CA-125 in pelvic inflammatory disease and pregnancy. Cancer 57, 1327-1329.
10. Hoefs, S.C. (1990) Spontaneous bacterial peritonitis: prevention and therapy. Hepatology, 12, 776-781.
11. Jacobs, I. & Bast, R.C., Jr. (1989) The CA-125 tumor-associated antigen. A review of the literature. Hum. Reprod., 4, 1-12.
12. Jager, W., Diedrich, K. & Wildt, L. (1987) Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil. Steril., 47, 675-678.
13. Kiluk, M.S., Rolkowski, R., Zawadzki, R.J. & Wojtukiewicz, M.Z. (2002) Usefulness of CEA, CA-15-3 and CA-125 tumor markers in the differential diagnostics of peritoneal effusion. Pol. Merkuriusz Lek. 87, 77-83.
14. Krasnicki, D. (2001) Serum and peritoneal fluid CA-125 concentration in women with endometriosis. Ginekol. Pol., 72, 1365-1359.
15. Mezger, J., Wilmanns, W. & Lamerz, R. (1998) Elevated serum CA-125 levels in patients with benign ascitis or pleural effusions. Tumor Biol., 9, 47-52.
16. Miralles, C., Orea, M., Espana, P., Proviencio, M., Sanchez, A., Cantos, B., Cubedo, R., Carcereny, E., Bonilla, F. & Gea, T. (2003) Cancer Antigen 125 associated with multiple benign and malignant pathologies. Ann. Surg. Oncol., 10, 150-154.
17. Molina, R., Ballesta, A.M. & Casals, E. (1985) Value of CA-125 antigen as tumor marker: Preliminary results. Protides Biol. Fluids, 32, 613-617.
18. Molina, R., Filella, X., Bruix, J., Mengual, P., Bosch, J., Calvet, X., Jo, C. & Ballesta, A.M. (1991) Cancer antigen CA-125 in serum and ascitic fluid of patients with liver diseases. Clin. Chem., 37, 1379-1383.
19. Molina, R., Filella, X., Jo, J. & Ballesta, A.M. (1998) CA-125 in biological fluids. Int. J. Biol. Markers., 13, 224-230.
20. Ozasa, H., Noda, Y. & Mori, T. (1987) Progesterone increases serum CA-125 in endometriosis. Fertil. Steril., 47, 699-701.
21. Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C. & Williams, R. (1973) Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg., 60, 646-649.
22. Ricolleau, G., Chatal, J.F. & Fumoleau, P. (1984) Radioimmunassay of the CA-125 antigen in ovarian carcinoma. Advantages compared with CA 19.9 and CEA. Tumor Biol., 5, 151-159.
23. Sanusi, A.A., Zweers, M.M., Weening, J.J., de Waart, D.R., Struijk, D.G. & Krediet, R.T. (2001) Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Perit. Dial. Int., 5, 495-500.
24. San, R. (2001) Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am. J. Gastroenterol., 96 253-254.
25. Sedlaczek, P., Frydecka, I., Gabrys, M., Van Dalen, A. & Einarsson, R., Harlozinska, A. (2002) Comparative analysis of CA-125, tissue polypeptide specific antigen andsoluble interleukin-2 receptor alpha levels in sera, cyst and ascetic fluids from patients with ovarian carcinoma. Cancer, 95, 1886-1893.
26. Sehouli, J., Akdogan, Z., Heinze, T., Ronsgen, D., Stengel, D., Mustea, A. & Lichtenegger, W. (2003) Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res., 23, 1115-1118.
27. Sevinc, A., Camci, C., Turk, H.M. & Buyukberber, S. (2003) How to interpret serum CA 125 levels in patients with serosal involvement ? A clinical dilemma. Oncology, 65, 1-6.
28. Shen-Gunther, J. & Mannel, R.S. (2002) Ascites as a predictor of ovarian malignancy. Gynecol. Oncol., 87, 77-83.
29. Sjoval, K., Nilsson, B. & Einhorn, N. (2002) The significance of serum CA-125 elevation in malignant and nonmalignant diseases. Gynecol. Oncol., 85, 175-178.
30. Topalak, O., Saygili, U., Soytürk, M., Karaca, N., Batur, Y., Uslu, T. & Erten, O. (2002) Serum pleural effusion and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases. A compparative study. Gynecol. Oncol., 85, 108-113.
31. Uenishi, T., Kubo, S., Hirohashi, K., Tanaka, H., Shuto, T., Yamamoto, T. & Nishiguchi, S. (2003) Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br. J. Cancer, 88, 1894-1899.
32. Zahedi, K. & Mortensen, R.F. (1986) Macrophage tumoricidal activity induced by human C-reactive protein. Cancer Res., 46 5077-5083.
33. Zeimet, A.G., Marth, C., Offner, F.A., Obrist, P., Uhl-Steidl, M., Feichtinger, H., Stadlmann, S., Daxenbichler, G. & Dapunt, O. (1996) Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol. Oncol. 62, 384-389.
34. Zuckerman, E., Lanir, A., Sabo, E., Rosenvald-Zuckerman, T., Matter, I., Yeshurun, D. & Eldar, S. (1999) Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am. J. Gastroenterol., 94, 1613-1618.
35. Zweig, M.H. & Camphell, G. (1993) Receiver operating characteristic(ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem., 39, 561-577.